PureTech Health
Edit

PureTech Health

https://www.puretechhealth.com
Last activity: 22.10.2024
Active
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 25 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Half Year Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.
Mentions
44
Location: United States, Massachusetts, Boston
Employees: 51-200
Phone:52928
Investment Type: Venture Capital

Mentions in press and media 44

DateTitleDescription
22.10.2024Seaport Therapeutics: $225 Million (Series B) Raised To Advance Novel Neuropsychiatric MedicinesSeaport Therapeutics—a clinical-stage biopharmaceutical company advancing novel neuropsychiatric medicines with a proven strategy and team—announced the closing of an oversubscribed $225 million Series B financing round. General Atlantic, a...
21.10.2024Seaport Therapeutics Closes $225M Series B Financing RoundSeaport Therapeutics, a Boston, MA-based biopharmaceutical company that is developing novel neuropsychiatric medicines, raised $225M in Series B funding. The round, which brought the total amount to $325M, was led by General Atlantic, with ...
11.06.2024QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of DirectorsIndustry veteran Williamson brings nearly three decades' experience as a leader in neuroscience R&D at organizations including Eli Lilly and Company, Lundbeck, Parexel, and Acadia Pharmaceuticals Former Karuna CFO Brown brings more than...
22.05.2024Carbon Biosciences Announces New Appointments to Board of Directors and Scientific Advisory Board- Carol Ann Satler, MD, PhD, FACC, FAHA, FAAP joins the Board of Directors, adding key clinical experience to guide ongoing nonclinical development in cardiac and pulmonary diseases - - Lloyd Klickstein, MD, PhD joins the Scientific Advisor...
12.12.2022PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health MonitoringAI vocal biomarker company will use funding to accelerate its commercial growth, expand its platform into new health conditions, and enter new geographies PureTech Health plc, a clinical-stage biotherapeutics company, noted that its Founded...
18.08.2022Through the lymph nodes it goes — re­searchers de­vel­op a can­cer drug that avoids tox­i­c­i­ties by skirt­ing the liv­erPI3K is a pro­tein that is part of a path­way that reg­u­lates cell growth, sur­vival and me­tab­o­lism — earn­ing it the in­scrip­tion of mas­ter reg­u­la­tor for can­cer. How­ev­er, while a num­ber of PI3K in­hibitor drugs have been ap­pr...
10.11.2021PureTech Health plc PureTech Receives Approximately $100 Million from Sale of a Portion of Founded Entity Shares - Form 6-KPureTech Health plc PureTech Receives Approximately $100 Million from Sale of a Portion of Founded Entity Shares PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeuti...
05.10.2021PureTech Health : Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDAPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vedanta Biosciences (“Vedanta”) today announced that its Phase 2 clinical tri...
21.07.2021PureTech Health : Founded Entity Vedanta Biosciences Completes $68 Million Series D FinancingPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, announces that its Founded Entity, Vedanta Biosciences (“Vedanta”), completed a $68 million Series D financing and provid...
26.05.2021PURETECH HEALTH PLC PureTech Health : Founded Entity Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital TherapeuticsPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced that its Founded Entity, Akili Interactive (“Akili”), has secured $160 million of combined equity and deb...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In